Show Summary Details
Page of

Osteoporosis in men 

Osteoporosis in men
Chapter:
Osteoporosis in men
Author(s):

Birgit C. Hanusch

, Stephen P. Tuck

, and Roger M. Francis

DOI:
10.1093/med/9780198713340.003.0014
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 08 April 2020

Male osteoporosis is common, with a 1 in 5 lifetime risk of fracture over the age of 50 years.

Male osteoporosis is both underdiagnosed and undertreated.

Men with fractures have higher mortality than men without fractures, and this is higher than that found in women.

Secondary causes are very common in men with osteoporosis.

There is now evidence for the use of oral and intravenous bisphosphonates, strontium ranelate, teriparatide, and denosumab to treat male osteoporosis.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.